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Abstract
Background: Diabetes Mellitus (DM) is associated with adverse cardiovascular prognosis. However, the risk associated with
DM may vary between individuals according to their overall cardiovascular risk burden. Therefore, we aimed to determine
whether DM is associated with poor outcome in patients presenting with Acute Coronary Syndrome (ACS) according to the
index episode being a first or recurrent cardiovascular event.
Methods and Findings: We conducted a retrospective analysis of a prospective cohort study involving 2499 consecutively
admitted patients with confirmed ACS in 11 UK hospitals during 2003. Usual care was provided for all participants.
Demographic factors, co-morbidity and treatment (during admission and at discharge) factors were recorded. The primary
outcome was all cause mortality (median 2 year follow up), compared for cohorts with and without DM according to their
prior cardiovascular disease (CVD) disease status. Adjusted analyses were performed with Cox proportional hazards
regression analysis. Within the entire cohort, DM was associated with an unadjusted 45% increase in mortality. However, in
patients free of a history of CVD, mortality of those with and without DM was similar (18.8% and 19.7% respectively;
p=0.74). In the group with CVD, mortality of patients with DM was significantly higher than those without DM (46.7% and
33.2% respectively; p,0.001). The age and sex adjusted interaction between DM and CVD in predicting mortality was highly
significant (p=0.002) and persisted after accounting for comorbidities and treatment factors (p=0.006). Of patients free of
CVD, DM was associated with smaller elevation of Troponin I (p,0.001). However in patients with pre-existing CVD
Troponin I was similar (p=0.992).
Conclusions: DM is only associated with worse outcome after ACS in patients with a pre-existing history of CVD. Differences
in the severity of myocyte necrosis may account for this. Further investigation is required, though our findings suggest that
aggressive primary prevention of CVD in patients with DM may have beneficially modified their first presentation with (and
mortality after) ACS.
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Introduction
Diabetes Mellitus (DM) is widely acknowledged to increase the
risk of developing atherosclerosis in addition to doubling risk of
cardiovascular death [1]. Of particular relevance, Haffner et al
demonstrated that patients with DM, and no prior myocardial
infarction (MI) suffered future MI at a rate equal to non-diabetic
patients with a history of MI [2], a group warranting aggressive
secondary preventative therapy. This underlies guidance that the
presence of DM alone, in individuals free of overt cardiovascular
disease (CVD), warrants the use of similarly aggressive primary
prevention strategies [3,4]. Furthermore, the OASIS investigators
demonstrated that DM conferred added risk of cardiovascular
mortality after unstable angina or non-Q wave MI in patients with
or without a prior history CVD [5]. However, more recent work
has contradicted these findings [6,7]. Some of this data has shown
that the cardiovascular risk attributable to DM is heterogeneous and
dependent on the overall burden of cardiovascular risk factors in
individual patients [7]. Hence, one might expect that the aggressive
risk reduction measures now targeted at patients with DM and no
prior CVD makes the mortality risk attributable to DM differ
between patients with first or recurrent cardiovascular events.
Furthermore, improved screening for DM may have resulted in
earlier diagnosis of the disorder, potentially reducing the CV risk of
current trial cohorts with DM, when compared with historical
groups, such as Haffner et al’s. In order to investigate this hypothesis
we conducted an analysis of observational data pertaining to a
contemporary cohort of acute coronary syndrome (ACS) sufferers.
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Data collection
A retrospective analysis of the EMMACE-II observational cohort
study was performed [8]. This examined outcomes in 2499
consecutively admitted, unselected patients with the diagnosis of
ACSconfirmedbycardiologists;specifically,atleasttwoofischaemic
symptoms, new ECG features compatible with ischaemia, and
biomarker elevation (cardiac troponin concentration above the 10%
CV taken 12–24 hours after the onset of symptoms or raised CK
concentration above twice the upper limit of normal) were required.
Data was collected from 11 hospitals in West Yorkshire, UK
between 28
th April and 28
th October 2003. All patients provided
written informed consent and the study was conducted with
appropriate local and regional ethics committee approval in
accordance with the declaration of Helsinki. Potential participants
were identified using a comprehensive search of clinical coding data,
coronary care registers and biochemistry laboratory cardiac
biomarker results. Detailed data on patient demographics, medical
history, index event characteristics and management were collected
and all cause mortality data (median 2 years) was provided by the
United Kingdom Office for National Statistics.
Individuals with DM were identified on the basis of past history
documented in the medical records, or the receipt of DM-related
dietary or pharmacologic intervention prior to the index event.
HistoryofCVD was defined by thepresenceofany prior myocardial
infarction,angina, cerebrovascular event,peripheralvascular disease
or coronary revascularisation procedure. Patient age, heart rate and
systolic blood pressure data were collected immediately on hospital
admission. Chronic renal impairment refers to estimated glomerular
filtration rate ,30 ml/min/1.73 m
2 (Cockroft-Gault method) and
heart failure to any previous diagnosis. Killip class (grades 1 to 4
indicating increasingly severe signs of heart failure) pertains to the
highest recording during admission. Troponin I (TnI) data was
collected using the Beckman Coulter AccuTnI assay. Revascularisa-
tion refers to percutaneous coronary intervention (PCI) or coronary
artery bypass grafting performed during the inpatient or early post
discharge phase; reperfusion refers to use of thrombolysis or primary
PCI. Secondary preventative pharmacotherapy use was defined at
hospital discharge.
Statistical analysis
All statistical analyses were performed using SPSS version 13.0
(SPSS Inc., Chicago, Illinois, USA). Continuous data are presented
as mean (standard error) and categorical data as number
(percentage). Groups were compared using Student’s T-test or
Mann-Whitney tests (non-normally distributed data) for continuous
data and Pearson x
2 for categorical data using two-sided tests. Crude
group survival data were compared using log rank tests. Statistical
significance was accepted at p,0.05, though when interpreting the
multiple comparisons of cohort characteristics displayed inTable 1 a
value of p,0.0028 should be used (Bonferroni correction). Cox
proportional hazards analysis was used to determine the significance
of interaction between DM and CVD in predicting survival; the
interaction term was additionally corrected for demographic and
clinical variables as outlined later. Covariates were selected prior to
Table 1. Cohort characteristics.
No CVD p value CVD p value
No DM DM No DM DM
n=950 n=117 n=1060 n=300
Deaths 187 (19.7) 22 (18.8) 0.74* 352 (33.2) 140 (46.7) ,0.001*
Age (years) 65.7 (0.5) 67.6 (1.2) 0.192 73.8 (0.4) 72.7 (0.6) ,0.001
Gender (male) 65.3 (620) 65 (76) 0.95 60 (636) 56 (168) 0.213
Cigarette smoking 39.4 (374) 9.4 (11) ,0.001 19.8 (210) 11(33) ,0.001
Chronic Renal Impairment 1.1 (10) 7.7 (9) ,0.001 6.3 (66) 8.1 (24) 0.271
Heart Failure 2.6 (25) 3.4 (4) 0.63 10.1 (106) 12.5 (37) 0.234
Systolic BP (mmHg) 142.9 (1.0) 144.5 (2.6) 0.338 140.6 (0.9) 143.1 (1.8) 0.824
Heart Rate (bpm) 82.5 (0.7) 84.2 (2.2) 0.82 83.4 (0.8) 90.8 (1.3) 0.234
Random Glucose (mmol/l) 7.5 (0.1) 12 (0.5) ,0.001 7.3 (0.1) 12.1 (0.4) ,0.001
Troponin I (ng/ml) 15.7 (0.9) 9.5 (1.7) ,0.001 7 (0.6) 7.4 (1.0) 0.992
Creatinine Kinase (U/l) 885 (50) 552 (78) ,0.001 451 (34) 413 (50) 0.447
Killip Class 1.26 (0.02) 1.35 (0.06) 0.23** 1.39 (0.02) 1.46 (0.04) 0.065**
ST elevation 39.5 (374) 29.1 (34) 0.029 18.1 (191) 15.2 (45) 0.234
Revascularisation 19.8 (187) 21.4 (25) 0.695 15.8 (166) 11 (33) 0.038
Reperfusion 31.9 (303) 24.8 (29) 0.115 10.8 (114) 11 (33) 0.898
Aspirin 80.6 (752) 79.5 (93) 0.775 72.5 (754) 68.7 (206) 0.194
Statin 79.2 (738) 85.2 (98) 0.128 73.6 (767) 76.1 (220) 0.387
ACE inhibitor 60.9 (573) 71.6 (83) 0.026 56.6 (589) 62.7 (183) 0.062
Beta-blocker 69.5 (648) 70.2 (80) 0.887 55.9 (580) 51.2 (149) 0.157
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Within the entire cohort 17.2% of patients were known to suffer
from DM and 58% had established CVD. The crude mortality of
patients with and without DM was 38.8% and 26.8%, respectively
(relative risk 1.45) over 4030 patient-years of follow up. However,
for the cohort without prior CVD, patients with and without DM
exhibited similar mortality (18.8% and 19.7% respectively;
Hazard Ratio associated with DM 0.95; p=0.74 by log rank;
Figure 1). In contrast, in the cohort with known CVD, patients
with DM had a significantly higher mortality than those without
DM (46.7% and 33.2% respectively; Hazard ratio associated with
DM 1.41; p,0.001 by log rank). Confirming the observation that
DM confers differing mortality risk according to presentation with
first or recurrent ACS, the interaction between CVD and DM in
predicting mortality was significant (p=0.039).
Cohort characteristics
The characteristics of patients with and without CVD,
according to their DM status, are detailed in Table 1. In patients
free of prior CVD, DM was associated with lower rates of ST-
elevation MI (29.1% vs. 39.5%; p=0.029); this contrasts with
similar rates of ST elevation in patients with known CVD,
independent of DM status (p=0.234). Troponin I, an index of
myocyte necrosis, was significantly lower in patients with DM and
no prior CVD, compared with patients without DM (p,0.001)
suggesting smaller ‘infarct size’. In contrast, the cohort with known
CVD exhibited similar troponin elevations independent of DM
status (p=0.992); the interaction between DM and CVD in
predicting TnI was significant (p=0.002).
Adjusted mortality data
After adjusting for age and gender differences between groups
the interaction between DM and CVD in predicting mortality was
highly significant (p=0.002). Further adjustment for comorbidity
and treatment factors outlined in Table 1 (Chronic renal
impairment, heart failure, reperfusion therapy, early revascular-
isation; use of aspirin, clopidogrel, statins, ACE inhibitors and
beta-adrenoreceptor antagonists) did not result in loss of this
interaction (p,0.006). However after accounting for ‘Troponin I
as a surrogate for infarct size’, the interaction between CVD and
DM in predicting mortality lost statistical significance (p=0.056)
suggesting differences in ‘infarct size’ may account for some of our
observations. Table 2 provides hazard ratios for the risk
attributable to DM in cohorts with and without prior CVD for
each of these adjusted models.
Alternative CVD definitions
The presented analyses defined CVD as the presence of any
prior myocardial infarction, angina, cerebrovascular event,
peripheral vascular disease or coronary revascularisation proce-
dure. Importantly, our observations persist when changing the
definition of CVD to 1) exclude cases defined solely on the basis of
angina; 2) exclude cases defined solely on the basis of angina, or
coronary revascularization (Data not shown).
Discussion
Our study of a contemporary cohort of ACS patients suggests that
the notion of DM increasing mortality risk in all ACS sufferers needs
to be revisited. The ability to predict high risk groups after ACS is a
crucial aspect of day-to-day management of individual patients, and
is also important in guiding allocation of limited resources. Whilst
DM is undoubtedly associated with poor outcome in entire ACS
cohorts [1], we have shown that its negative prognostic value is
greatest in patients with recurrent CVD, as opposed to those whose
ACS is their first CVD presentation.
Figure 1. Cohort mortality. Kaplan-Meier curves illustrating mortality of the 4 study cohorts according to pre-existing CVD and DM status.
doi:10.1371/journal.pone.0003483.g001
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observational study, though the differences in ACS subtype and
extent of myocyte necrosis between groups is intriguing. Indeed,
the addition of TnI as an index of ‘infarct size’ to our adjusted
model resulted in loss of the interaction between CVD and DM in
predicting mortality, even after accounting for other demographic,
comorbid and treatment factors. In other words, the smaller
‘infarct size’ of patients with DM and no prior CVD, compared to
patients without DM or prior CVD, may account for their similar
mortality rates.
Whilst the smaller ‘infarct size’ of patients with DM in the cohort
free of prior CVD is significant, we again cannot explain this due to
the observational nature of the study. However, patients with DM
are known to exhibitmore diffuse coronary artery disease and it may
be that their vulnerable plaques are more distal [9,10], so
threatening a smaller volume of myocardium. Equally, the well
documented decline in incidence of ST elevation MI [11], which is
attributed to increasingly aggressive primary and secondary
prevention strategies, may be relevant. Since the publication of
Haffner et al’s work a decade ago [2], aggressive primary prevention
of CVD in patients with DM has become routine [3,4]. This may
have ‘stabilised’ the sub-clinical atherosclerosis of patients with DM,
reducing their infarct size below that of non-diabetic patients who
may have received less effective CVD prevention measures as a
group. Such changes in primary prevention may also explain the
differences between our study and the OASIS investigators whose
cohort was studied in 1995–6 [5].
Study limitations
A number of limitations should be borne in mind when reading
the present report. The analysis would have benefited from
measurements of other novel and traditional cardiovascular risk
factors such as albuminuria and obesity, in addition to detailed
analysis of preventative therapy received by patients prior to the
index event. Future investigation as to why diabetes is associated
with less mortality risk in patients free of prior CVD would benefit
from their inclusion. Furthermore, rates of secondary preventative
therapy provision at hospital discharge in our study appeared
counterintuitive, with prior CVD sufferers less likely to receive
statins and ACE inhibitors than patients suffering their first CVD
event. Whether this relates to the greater age and co-morbidity of
prior CVD sufferers (resulting in reluctance to prescribe in case of
relative contraindications, drug interactions or side-effects) is
unclear. Again further studies addressing this would be useful.
Future studies
Further clinical trials may serve to test our observations without
the inherent disadvantages of observational research. However,
our work raises a number of important questions. First, if
aggressive primary prevention of CVD in patients with DM has
reduced their mortality to a level comparable to those without
DM, should we be targeting more aggressive primary preventative
management to patients without DM? Second, if it is possible to
reduce the mortality of patients with DM and first ACS to a rate
comparable to patients without DM, can we maintain this
achievement by more aggressively preventing further CV events?
Our data suggests there is capacity to improve the use of evidence
based secondary preventative measures in this group. Equally, if
the mortality of patients with DM and no prior CVD has been
reduced to the level of patients without DM how can we mirror
this in patients presenting with recurrent ACS? This is perhaps the
most challenging question and may well require novel therapies in
addition to aggressive adoption of currently accepted therapies.
Such questions will undoubtedly become increasingly important as
the prevalence of DM continues to rise.
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